Bluebird bio Inc
BLUE
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
23.1% downsideOvervalued by 23.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $48.67 Million |
|---|---|
| Enterprise Value | $128.01 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-24.84 |
| Beta | 0.37 |
| Outstanding Shares | 9,751,000 |
Return
| Return on Equity | 345.59% |
|---|---|
| Return on Assets | -67.57% |
| Return on Invested Capital | 1060.71% |
Valuation & Multiples
| P/E Ratio | -0.84 |
|---|---|
| PEG | 1.44 |
| Price to Sales | 0.5 |
| Price to Book Ratio | -0.83 |
| Enterprise Value to Revenue | 1.23 |
| Enterprise Value to EBIT | -0.63 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.23 |
| Debt to Equity | -2.73 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Bluebird bio Inc
Relevant Senate Committees
Controls Medicare and Medicaid reimbursement policy; since Bluebird's therapies cost millions, government reimbursement is critical for success.
Allocates specific funding to the FDA and NIH, directly impacting the resources available for drug review and basic research.
Directly oversees the FDA and the drug approval process; members are likely to possess non-public information regarding regulatory frameworks.
Oversees intellectual property and patent laws, which are fundamental to the valuation and protection of Bluebird's gene therapy platform.